RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com.
Media Resources
Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.
For media interested in Verastem Oncology, please contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.
To stay updated on the latest news about Verastem Oncology, sign up for alerts.
Previous and Upcoming Events
Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.
RBC Capital Markets Global Healthcare Conference
05/17/2023 2:05 PM (EDT)
JMP Securities Life Sciences Conference
05/16/2023 1:00 PM (EDT)
Stifel 2023 Virtual Targeted Oncology Days
04/25/2023 2:30 PM (EDT)
01/24/2023 6:00 PM (EST)
01/28/2022 9:30 AM (EST)
H.C. Wainwright BIOCONNECT Conference
01/10/2022 7:00 AM (EST)
Jefferies London Healthcare Conference
11/18/2021 3:00 AM (EST)
Cantor Virtual Global Healthcare Conference
09/27/2021 4:00 PM (EDT)
H.C. Wainwright 23rd Annual Global Investment Conference
09/13/2021 7:00 AM (EDT)
Jefferies Virtual Healthcare Conference
06/01/2021 4:00 PM (EDT)
H.C. Wainwright Global Life Sciences Conference
03/09/2021 7:00 AM (EST)
H.C. Wainwright BioConnect 2021 Conference
01/11/2021 6:00 AM (EST)
12/17/2020 10:30 AM (EST)
Cantor Virtual Global Healthcare
09/17/2020 3:20 PM (EDT)
Verastem Oncology Updated Clinical Data in LGSOC from Phase 1/2 FRAME Study Conference Call
09/16/2020 8:00 AM (EDT)
H.C. Wainwright 22nd Annual Global Investment Conference
09/14/2020 1:30 PM (EDT)
Jefferies 2020 Healthcare Conference
06/04/2020 2:30 PM (EDT)
Verastem Oncology AACR Virtual Annual Meeting Data Conference Call
04/27/2020 8:00 AM (EDT)
Verastem Oncology Conference Call
02/28/2020 8:00 AM (EST)
Verastem Oncology Conference Call
01/08/2020 4:00 PM (EST)
Verastem Oncology Third Quarter 2019 Financial Results Conference Call
10/29/2019 4:30 PM (EDT)
Verastem Oncology™ at 2019 Cantor Global HC Conference
10/03/2019 8:20 AM (EDT)
Verastem Oncology™ at 21st Annual H.C. Wainwright Global Investment Conference
09/10/2019 10:25 AM (EDT)
Verastem Oncology Second Quarter 2019 Financial Results Conference Call
08/01/2019 4:30 PM (EDT)
Verastem Inc the Rodman and Renshaw 17th Annual Global Investment Conference
09/10/2015 3:50 PM (EDT)
Articles Featuring Verastem Oncology
Mirati and Verastem Combine to Address Unmet Need in KRAS G12C–Mutant NSCLC
01/07/2022 OncLive
Susana Banerjee on Ovarian Cancer Novel Combination Therapy Under Study
11/18/2021 The ASCO Post
11/06/2021 Daily Mail
‘Highly effective’ ovarian cancer treatment could help thousands of women
09/19/2021 The Guardian
Global Study Explores RAF/MEK/FAK Combo in Recurrent LGSOC, With or Without KRAS Mutations
08/06/2021 Targeted Oncology
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian Cancer
06/18/2021 OncLive
Verastem Wins Breakthrough Nod for Combo Therapy in Ovarian Cancer
05/24/2021 Endpoints
05/24/2021 OncLive
FDA Grants Breakthrough Therapy Designation to Combination for Recurrent Ovarian Cancer
05/24/2021 Healio
The RAS Pathway and Cancer: Regulation, Challenges and Therapeutic Progress
05/04/2021 Technology Networks
Personalizing Therapy With VS-6766, Defactinib for Patients With KRAS+ NSCLC
04/23/2021 Oncology Learning Network
Clinical Trial to Find Optimal Regimen of VS-6766 With or Without Defactinib for LGSOC
04/23/2021 Oncology Learning Network
Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC
01/13/2021 DocWire News
01/06/2021 OncLive
12/23/2020 Oncology Tube
In the Clinic for December 15, 2020
12/15/2020 BioWorld
12/09/2020 BioPharma Journal
Drs. Banerji and Pachter Talk About RAF/MEK Inhibitor in RAS Mutant Tumors
12/02/2020 DocWire News
Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer
11/30/2020 Precision Oncology News
11/30/2020 Pharma Premium
11/06/2020 Oncology Tube
KRAS Inhibitors Show Promise in Early Studies
11/05/2020 Cancer Health
Contact
Lisa Buffington
Corporate Communications
(781) 292-4502
media@verastem.com